Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.48 |
| ▸ | MEN1 | O00255 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1031573 | 0.87 | KMT2A (0.52) | KMT2AMEN1ALDH1A1MAPTNPSR1 | |
| SCHEMBL1029485 | 0.80 | HSD11B1 (0.46) | ALDH1A1HSD11B1 | |
| SCHEMBL1028758 | 0.79 | GRIN2B (0.44) | KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1031082 | 0.78 | ALDH1A1 (0.44) | KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL1029934 | 0.77 | ALDH1A1 (0.56) | KMT2AMEN1ALDH1A1LMNAHSD11B1 | |
| SCHEMBL1031429 | 0.74 | MEN1 (0.47) | KMT2AMEN1 | |
| SCHEMBL1028177 | 0.74 | CNR2 (0.48) | KMT2AMEN1ALDH1A1MAPTNPSR1 | |
| SCHEMBL1029313 | 0.74 | L3MBTL3 (0.46) | KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL1028497 | 0.73 | PRKAA2 (0.44) | ALDH1A1MAPTLMNA | |
| SCHEMBL1031812 | 0.73 | HPGD (0.49) | ALDH1A1MAPTNPSR1LMNAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968591-B2 | 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their use in medicaments | GRUENENTHAL GMBH (DE) | 2011-06-28 | — | — | US | claimed |
| EP-2035375-B1 | 1,3-DISUBSTITUTED 4-METHYL-1H-PYRROLE-2-CARBOXAMIDES AND THEIR USE FOR THE MANUFACTURE OF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2011-01-19 | — | — | EP | claimed |
| US-20090137573-A1 | 1,3-Disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their Use in Medicaments | GRUENENTHAL GMBH (DE) | 2009-05-28 | — | — | US | claimed |
| EP-2035375-A1 | 1,3-DISUBSTITUTED 4-METHYL-1H-PYRROLE-2-CARBOXAMIDES AND THEIR USE FOR THE MANUFACTURE OF MEDICAMENTS | Grünenthal GmbH (DE) | 2009-03-18 | — | — | EP | claimed |
| WO-2007141039-A1 | 1,3-DISUBSTITUTED 4-METHYL-1H-PYRROLE-2-CARBOXAMIDES AND THEIR USE FOR THE MANUFACTURE OF MEDICAMENTS | Grünenthal GmbH (DE) | 2007-12-13 | — | — | WO | claimed |
| US-7968591-B2 | 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their use in medicaments | GRUENENTHAL GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| EP-2035375-B1 | 1,3-DISUBSTITUTED 4-METHYL-1H-PYRROLE-2-CARBOXAMIDES AND THEIR USE FOR THE MANUFACTURE OF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2011-01-19 | — | — | EP | disclosed |
| US-20090137573-A1 | 1,3-Disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their Use in Medicaments | GRUENENTHAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| EP-2035375-A1 | 1,3-DISUBSTITUTED 4-METHYL-1H-PYRROLE-2-CARBOXAMIDES AND THEIR USE FOR THE MANUFACTURE OF MEDICAMENTS | Grünenthal GmbH (DE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007141039-A1 | 1,3-DISUBSTITUTED 4-METHYL-1H-PYRROLE-2-CARBOXAMIDES AND THEIR USE FOR THE MANUFACTURE OF MEDICAMENTS | Grünenthal GmbH (DE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137573-A1 | 1,3-Disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their Use in Medicaments | OPRL1, TPH1, OPRK1 | KMT2A 1507/4885MEN1 4776/4885ALDH1A1 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.